While we did not observe any significant differences in ABO compatibility between the three groups, BM grafts, proven to decrease the risk of chronic GvHD [41], were more frequently used in the Haplo-HSCT group than in the HLA-matched groups. Here, ABO is linked to chronic graft versus host disease.